0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Adult Malignant Glioma Treatment Market Research Report 2024
Published Date: July 2024
|
Report Code: QYRE-Auto-12R14095
Home | Market Reports | Health| Health Conditions| Cancer
Global Adult Malignant Glioma Treatment Market Research Report 2023
BUY CHAPTERS

Global Adult Malignant Glioma Treatment Market Research Report 2024

Code: QYRE-Auto-12R14095
Report
July 2024
Pages:94
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Adult Malignant Glioma Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Adult Malignant Glioma Treatment Market

Adult Malignant Glioma Treatment Market

Malignant gliomas, tumors derived from the neuroepithelium are collectively referred to as gliomas (gliomas), accounting for 40-50% of brain tumors, and are the most common intracranial malignant tumors. According to pathology, it can be divided into astrocytoma, medulloblastoma, glioblastoma multiforme, ependymoma, oligodendroglioma and so on.
The global Adult Malignant Glioma Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Adult Malignant Glioma Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adult Malignant Glioma Treatment.

Report Scope

The Adult Malignant Glioma Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Adult Malignant Glioma Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adult Malignant Glioma Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Adult Malignant Glioma Treatment Market Report

Report Metric Details
Report Name Adult Malignant Glioma Treatment Market
CAGR 5%
Segment by Type
  • Chemotherapy
  • Targeted Drug Therapy
Segment by Application
  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma
  • Anaplastic Oligodendroglioma
  • Anaplastic Oligoastrocytoma
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Arbor Pharmaceuticals, Pfizer,Inc, AbbVie, Inc, Amgen, Inc, Bristol-Myers Squibb Company, Sun Pharmaceuticals Ltd, Teva Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, Bayer, SL Pharm, Boan Biotech
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Adult Malignant Glioma Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Adult Malignant Glioma Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Adult Malignant Glioma Treatment Market report?

Ans: The main players in the Adult Malignant Glioma Treatment Market are Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Arbor Pharmaceuticals, Pfizer,Inc, AbbVie, Inc, Amgen, Inc, Bristol-Myers Squibb Company, Sun Pharmaceuticals Ltd, Teva Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, Bayer, SL Pharm, Boan Biotech

What are the Application segmentation covered in the Adult Malignant Glioma Treatment Market report?

Ans: The Applications covered in the Adult Malignant Glioma Treatment Market report are Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Other

What are the Type segmentation covered in the Adult Malignant Glioma Treatment Market report?

Ans: The Types covered in the Adult Malignant Glioma Treatment Market report are Chemotherapy, Targeted Drug Therapy

1 Adult Malignant Glioma Treatment Market Overview
1.1 Product Overview and Scope of Adult Malignant Glioma Treatment
1.2 Adult Malignant Glioma Treatment Segment by Type
1.2.1 Global Adult Malignant Glioma Treatment Market Value Comparison by Type (2024-2030)
1.2.2 Chemotherapy
1.2.3 Targeted Drug Therapy
1.3 Adult Malignant Glioma Treatment Segment by Application
1.3.1 Global Adult Malignant Glioma Treatment Market Value by Application: (2024-2030)
1.3.2 Glioblastoma Multiforme
1.3.3 Anaplastic Astrocytoma
1.3.4 Anaplastic Oligodendroglioma
1.3.5 Anaplastic Oligoastrocytoma
1.3.6 Other
1.4 Global Adult Malignant Glioma Treatment Market Size Estimates and Forecasts
1.4.1 Global Adult Malignant Glioma Treatment Revenue 2019-2030
1.4.2 Global Adult Malignant Glioma Treatment Sales 2019-2030
1.4.3 Global Adult Malignant Glioma Treatment Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Adult Malignant Glioma Treatment Market Competition by Manufacturers
2.1 Global Adult Malignant Glioma Treatment Sales Market Share by Manufacturers (2019-2024)
2.2 Global Adult Malignant Glioma Treatment Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Adult Malignant Glioma Treatment Average Price by Manufacturers (2019-2024)
2.4 Global Adult Malignant Glioma Treatment Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Adult Malignant Glioma Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Adult Malignant Glioma Treatment, Product Type & Application
2.7 Adult Malignant Glioma Treatment Market Competitive Situation and Trends
2.7.1 Adult Malignant Glioma Treatment Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Adult Malignant Glioma Treatment Players Market Share by Revenue
2.7.3 Global Adult Malignant Glioma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Adult Malignant Glioma Treatment Retrospective Market Scenario by Region
3.1 Global Adult Malignant Glioma Treatment Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Adult Malignant Glioma Treatment Global Adult Malignant Glioma Treatment Sales by Region: 2019-2030
3.2.1 Global Adult Malignant Glioma Treatment Sales by Region: 2019-2024
3.2.2 Global Adult Malignant Glioma Treatment Sales by Region: 2025-2030
3.3 Global Adult Malignant Glioma Treatment Global Adult Malignant Glioma Treatment Revenue by Region: 2019-2030
3.3.1 Global Adult Malignant Glioma Treatment Revenue by Region: 2019-2024
3.3.2 Global Adult Malignant Glioma Treatment Revenue by Region: 2025-2030
3.4 North America Adult Malignant Glioma Treatment Market Facts & Figures by Country
3.4.1 North America Adult Malignant Glioma Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Adult Malignant Glioma Treatment Sales by Country (2019-2030)
3.4.3 North America Adult Malignant Glioma Treatment Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Adult Malignant Glioma Treatment Market Facts & Figures by Country
3.5.1 Europe Adult Malignant Glioma Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Adult Malignant Glioma Treatment Sales by Country (2019-2030)
3.5.3 Europe Adult Malignant Glioma Treatment Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Adult Malignant Glioma Treatment Market Facts & Figures by Country
3.6.1 Asia Pacific Adult Malignant Glioma Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Adult Malignant Glioma Treatment Sales by Country (2019-2030)
3.6.3 Asia Pacific Adult Malignant Glioma Treatment Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Adult Malignant Glioma Treatment Market Facts & Figures by Country
3.7.1 Latin America Adult Malignant Glioma Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Adult Malignant Glioma Treatment Sales by Country (2019-2030)
3.7.3 Latin America Adult Malignant Glioma Treatment Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Adult Malignant Glioma Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa Adult Malignant Glioma Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Adult Malignant Glioma Treatment Sales by Country (2019-2030)
3.8.3 Middle East and Africa Adult Malignant Glioma Treatment Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Adult Malignant Glioma Treatment Sales by Type (2019-2030)
4.1.1 Global Adult Malignant Glioma Treatment Sales by Type (2019-2024)
4.1.2 Global Adult Malignant Glioma Treatment Sales by Type (2025-2030)
4.1.3 Global Adult Malignant Glioma Treatment Sales Market Share by Type (2019-2030)
4.2 Global Adult Malignant Glioma Treatment Revenue by Type (2019-2030)
4.2.1 Global Adult Malignant Glioma Treatment Revenue by Type (2019-2024)
4.2.2 Global Adult Malignant Glioma Treatment Revenue by Type (2025-2030)
4.2.3 Global Adult Malignant Glioma Treatment Revenue Market Share by Type (2019-2030)
4.3 Global Adult Malignant Glioma Treatment Price by Type (2019-2030)
5 Segment by Application
5.1 Global Adult Malignant Glioma Treatment Sales by Application (2019-2030)
5.1.1 Global Adult Malignant Glioma Treatment Sales by Application (2019-2024)
5.1.2 Global Adult Malignant Glioma Treatment Sales by Application (2025-2030)
5.1.3 Global Adult Malignant Glioma Treatment Sales Market Share by Application (2019-2030)
5.2 Global Adult Malignant Glioma Treatment Revenue by Application (2019-2030)
5.2.1 Global Adult Malignant Glioma Treatment Revenue by Application (2019-2024)
5.2.2 Global Adult Malignant Glioma Treatment Revenue by Application (2025-2030)
5.2.3 Global Adult Malignant Glioma Treatment Revenue Market Share by Application (2019-2030)
5.3 Global Adult Malignant Glioma Treatment Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck & Co., Inc
6.1.1 Merck & Co., Inc Corporation Information
6.1.2 Merck & Co., Inc Description and Business Overview
6.1.3 Merck & Co., Inc Adult Malignant Glioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck & Co., Inc Adult Malignant Glioma Treatment Product Portfolio
6.1.5 Merck & Co., Inc Recent Developments/Updates
6.2 F. Hoffmann-La Roche Ltd
6.2.1 F. Hoffmann-La Roche Ltd Corporation Information
6.2.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.2.3 F. Hoffmann-La Roche Ltd Adult Malignant Glioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.2.4 F. Hoffmann-La Roche Ltd Adult Malignant Glioma Treatment Product Portfolio
6.2.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.3 Arbor Pharmaceuticals
6.3.1 Arbor Pharmaceuticals Corporation Information
6.3.2 Arbor Pharmaceuticals Description and Business Overview
6.3.3 Arbor Pharmaceuticals Adult Malignant Glioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Arbor Pharmaceuticals Adult Malignant Glioma Treatment Product Portfolio
6.3.5 Arbor Pharmaceuticals Recent Developments/Updates
6.4 Pfizer,Inc
6.4.1 Pfizer,Inc Corporation Information
6.4.2 Pfizer,Inc Description and Business Overview
6.4.3 Pfizer,Inc Adult Malignant Glioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer,Inc Adult Malignant Glioma Treatment Product Portfolio
6.4.5 Pfizer,Inc Recent Developments/Updates
6.5 AbbVie, Inc
6.5.1 AbbVie, Inc Corporation Information
6.5.2 AbbVie, Inc Description and Business Overview
6.5.3 AbbVie, Inc Adult Malignant Glioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.5.4 AbbVie, Inc Adult Malignant Glioma Treatment Product Portfolio
6.5.5 AbbVie, Inc Recent Developments/Updates
6.6 Amgen, Inc
6.6.1 Amgen, Inc Corporation Information
6.6.2 Amgen, Inc Description and Business Overview
6.6.3 Amgen, Inc Adult Malignant Glioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Amgen, Inc Adult Malignant Glioma Treatment Product Portfolio
6.6.5 Amgen, Inc Recent Developments/Updates
6.7 Bristol-Myers Squibb Company
6.6.1 Bristol-Myers Squibb Company Corporation Information
6.6.2 Bristol-Myers Squibb Company Description and Business Overview
6.6.3 Bristol-Myers Squibb Company Adult Malignant Glioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bristol-Myers Squibb Company Adult Malignant Glioma Treatment Product Portfolio
6.7.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.8 Sun Pharmaceuticals Ltd
6.8.1 Sun Pharmaceuticals Ltd Corporation Information
6.8.2 Sun Pharmaceuticals Ltd Description and Business Overview
6.8.3 Sun Pharmaceuticals Ltd Adult Malignant Glioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Sun Pharmaceuticals Ltd Adult Malignant Glioma Treatment Product Portfolio
6.8.5 Sun Pharmaceuticals Ltd Recent Developments/Updates
6.9 Teva Pharmaceutical Industries Limited
6.9.1 Teva Pharmaceutical Industries Limited Corporation Information
6.9.2 Teva Pharmaceutical Industries Limited Description and Business Overview
6.9.3 Teva Pharmaceutical Industries Limited Adult Malignant Glioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Teva Pharmaceutical Industries Limited Adult Malignant Glioma Treatment Product Portfolio
6.9.5 Teva Pharmaceutical Industries Limited Recent Developments/Updates
6.10 Emcure Pharmaceuticals Limited
6.10.1 Emcure Pharmaceuticals Limited Corporation Information
6.10.2 Emcure Pharmaceuticals Limited Description and Business Overview
6.10.3 Emcure Pharmaceuticals Limited Adult Malignant Glioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Emcure Pharmaceuticals Limited Adult Malignant Glioma Treatment Product Portfolio
6.10.5 Emcure Pharmaceuticals Limited Recent Developments/Updates
6.11 Bayer
6.11.1 Bayer Corporation Information
6.11.2 Bayer Adult Malignant Glioma Treatment Description and Business Overview
6.11.3 Bayer Adult Malignant Glioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Bayer Adult Malignant Glioma Treatment Product Portfolio
6.11.5 Bayer Recent Developments/Updates
6.12 SL Pharm
6.12.1 SL Pharm Corporation Information
6.12.2 SL Pharm Adult Malignant Glioma Treatment Description and Business Overview
6.12.3 SL Pharm Adult Malignant Glioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.12.4 SL Pharm Adult Malignant Glioma Treatment Product Portfolio
6.12.5 SL Pharm Recent Developments/Updates
6.13 Boan Biotech
6.13.1 Boan Biotech Corporation Information
6.13.2 Boan Biotech Adult Malignant Glioma Treatment Description and Business Overview
6.13.3 Boan Biotech Adult Malignant Glioma Treatment Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Boan Biotech Adult Malignant Glioma Treatment Product Portfolio
6.13.5 Boan Biotech Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Adult Malignant Glioma Treatment Industry Chain Analysis
7.2 Adult Malignant Glioma Treatment Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Adult Malignant Glioma Treatment Production Mode & Process
7.4 Adult Malignant Glioma Treatment Sales and Marketing
7.4.1 Adult Malignant Glioma Treatment Sales Channels
7.4.2 Adult Malignant Glioma Treatment Distributors
7.5 Adult Malignant Glioma Treatment Customers
8 Adult Malignant Glioma Treatment Market Dynamics
8.1 Adult Malignant Glioma Treatment Industry Trends
8.2 Adult Malignant Glioma Treatment Market Drivers
8.3 Adult Malignant Glioma Treatment Market Challenges
8.4 Adult Malignant Glioma Treatment Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
    Table 1. Global Adult Malignant Glioma Treatment Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Adult Malignant Glioma Treatment Market Value Comparison by Application (2024-2030) & (US$ Million)
    Table 3. Global Adult Malignant Glioma Treatment Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Adult Malignant Glioma Treatment Sales (K Units) of Key Manufacturers (2019-2024)
    Table 5. Global Adult Malignant Glioma Treatment Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Adult Malignant Glioma Treatment Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Adult Malignant Glioma Treatment Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Adult Malignant Glioma Treatment Average Price (US$/Unit) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Adult Malignant Glioma Treatment, Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Adult Malignant Glioma Treatment, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Adult Malignant Glioma Treatment, Product Type & Application
    Table 12. Global Key Manufacturers of Adult Malignant Glioma Treatment, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Adult Malignant Glioma Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adult Malignant Glioma Treatment as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Adult Malignant Glioma Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Adult Malignant Glioma Treatment Sales by Region (2019-2024) & (K Units)
    Table 18. Global Adult Malignant Glioma Treatment Sales Market Share by Region (2019-2024)
    Table 19. Global Adult Malignant Glioma Treatment Sales by Region (2025-2030) & (K Units)
    Table 20. Global Adult Malignant Glioma Treatment Sales Market Share by Region (2025-2030)
    Table 21. Global Adult Malignant Glioma Treatment Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Adult Malignant Glioma Treatment Revenue Market Share by Region (2019-2024)
    Table 23. Global Adult Malignant Glioma Treatment Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Adult Malignant Glioma Treatment Revenue Market Share by Region (2025-2030)
    Table 25. North America Adult Malignant Glioma Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Adult Malignant Glioma Treatment Sales by Country (2019-2024) & (K Units)
    Table 27. North America Adult Malignant Glioma Treatment Sales by Country (2025-2030) & (K Units)
    Table 28. North America Adult Malignant Glioma Treatment Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Adult Malignant Glioma Treatment Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Adult Malignant Glioma Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Adult Malignant Glioma Treatment Sales by Country (2019-2024) & (K Units)
    Table 32. Europe Adult Malignant Glioma Treatment Sales by Country (2025-2030) & (K Units)
    Table 33. Europe Adult Malignant Glioma Treatment Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Adult Malignant Glioma Treatment Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Adult Malignant Glioma Treatment Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Adult Malignant Glioma Treatment Sales by Region (2019-2024) & (K Units)
    Table 37. Asia Pacific Adult Malignant Glioma Treatment Sales by Region (2025-2030) & (K Units)
    Table 38. Asia Pacific Adult Malignant Glioma Treatment Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Adult Malignant Glioma Treatment Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Adult Malignant Glioma Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Adult Malignant Glioma Treatment Sales by Country (2019-2024) & (K Units)
    Table 42. Latin America Adult Malignant Glioma Treatment Sales by Country (2025-2030) & (K Units)
    Table 43. Latin America Adult Malignant Glioma Treatment Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Adult Malignant Glioma Treatment Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Adult Malignant Glioma Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Adult Malignant Glioma Treatment Sales by Country (2019-2024) & (K Units)
    Table 47. Middle East & Africa Adult Malignant Glioma Treatment Sales by Country (2025-2030) & (K Units)
    Table 48. Middle East & Africa Adult Malignant Glioma Treatment Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Adult Malignant Glioma Treatment Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Adult Malignant Glioma Treatment Sales (K Units) by Type (2019-2024)
    Table 51. Global Adult Malignant Glioma Treatment Sales (K Units) by Type (2025-2030)
    Table 52. Global Adult Malignant Glioma Treatment Sales Market Share by Type (2019-2024)
    Table 53. Global Adult Malignant Glioma Treatment Sales Market Share by Type (2025-2030)
    Table 54. Global Adult Malignant Glioma Treatment Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Adult Malignant Glioma Treatment Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Adult Malignant Glioma Treatment Revenue Market Share by Type (2019-2024)
    Table 57. Global Adult Malignant Glioma Treatment Revenue Market Share by Type (2025-2030)
    Table 58. Global Adult Malignant Glioma Treatment Price (US$/Unit) by Type (2019-2024)
    Table 59. Global Adult Malignant Glioma Treatment Price (US$/Unit) by Type (2025-2030)
    Table 60. Global Adult Malignant Glioma Treatment Sales (K Units) by Application (2019-2024)
    Table 61. Global Adult Malignant Glioma Treatment Sales (K Units) by Application (2025-2030)
    Table 62. Global Adult Malignant Glioma Treatment Sales Market Share by Application (2019-2024)
    Table 63. Global Adult Malignant Glioma Treatment Sales Market Share by Application (2025-2030)
    Table 64. Global Adult Malignant Glioma Treatment Revenue (US$ Million) by Application (2019-2024)
    Table 65. Global Adult Malignant Glioma Treatment Revenue (US$ Million) by Application (2025-2030)
    Table 66. Global Adult Malignant Glioma Treatment Revenue Market Share by Application (2019-2024)
    Table 67. Global Adult Malignant Glioma Treatment Revenue Market Share by Application (2025-2030)
    Table 68. Global Adult Malignant Glioma Treatment Price (US$/Unit) by Application (2019-2024)
    Table 69. Global Adult Malignant Glioma Treatment Price (US$/Unit) by Application (2025-2030)
    Table 70. Merck & Co., Inc Corporation Information
    Table 71. Merck & Co., Inc Description and Business Overview
    Table 72. Merck & Co., Inc Adult Malignant Glioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 73. Merck & Co., Inc Adult Malignant Glioma Treatment Product
    Table 74. Merck & Co., Inc Recent Developments/Updates
    Table 75. F. Hoffmann-La Roche Ltd Corporation Information
    Table 76. F. Hoffmann-La Roche Ltd Description and Business Overview
    Table 77. F. Hoffmann-La Roche Ltd Adult Malignant Glioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 78. F. Hoffmann-La Roche Ltd Adult Malignant Glioma Treatment Product
    Table 79. F. Hoffmann-La Roche Ltd Recent Developments/Updates
    Table 80. Arbor Pharmaceuticals Corporation Information
    Table 81. Arbor Pharmaceuticals Description and Business Overview
    Table 82. Arbor Pharmaceuticals Adult Malignant Glioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 83. Arbor Pharmaceuticals Adult Malignant Glioma Treatment Product
    Table 84. Arbor Pharmaceuticals Recent Developments/Updates
    Table 85. Pfizer,Inc Corporation Information
    Table 86. Pfizer,Inc Description and Business Overview
    Table 87. Pfizer,Inc Adult Malignant Glioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 88. Pfizer,Inc Adult Malignant Glioma Treatment Product
    Table 89. Pfizer,Inc Recent Developments/Updates
    Table 90. AbbVie, Inc Corporation Information
    Table 91. AbbVie, Inc Description and Business Overview
    Table 92. AbbVie, Inc Adult Malignant Glioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 93. AbbVie, Inc Adult Malignant Glioma Treatment Product
    Table 94. AbbVie, Inc Recent Developments/Updates
    Table 95. Amgen, Inc Corporation Information
    Table 96. Amgen, Inc Description and Business Overview
    Table 97. Amgen, Inc Adult Malignant Glioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 98. Amgen, Inc Adult Malignant Glioma Treatment Product
    Table 99. Amgen, Inc Recent Developments/Updates
    Table 100. Bristol-Myers Squibb Company Corporation Information
    Table 101. Bristol-Myers Squibb Company Description and Business Overview
    Table 102. Bristol-Myers Squibb Company Adult Malignant Glioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 103. Bristol-Myers Squibb Company Adult Malignant Glioma Treatment Product
    Table 104. Bristol-Myers Squibb Company Recent Developments/Updates
    Table 105. Sun Pharmaceuticals Ltd Corporation Information
    Table 106. Sun Pharmaceuticals Ltd Description and Business Overview
    Table 107. Sun Pharmaceuticals Ltd Adult Malignant Glioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 108. Sun Pharmaceuticals Ltd Adult Malignant Glioma Treatment Product
    Table 109. Sun Pharmaceuticals Ltd Recent Developments/Updates
    Table 110. Teva Pharmaceutical Industries Limited Corporation Information
    Table 111. Teva Pharmaceutical Industries Limited Description and Business Overview
    Table 112. Teva Pharmaceutical Industries Limited Adult Malignant Glioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 113. Teva Pharmaceutical Industries Limited Adult Malignant Glioma Treatment Product
    Table 114. Teva Pharmaceutical Industries Limited Recent Developments/Updates
    Table 115. Emcure Pharmaceuticals Limited Corporation Information
    Table 116. Emcure Pharmaceuticals Limited Description and Business Overview
    Table 117. Emcure Pharmaceuticals Limited Adult Malignant Glioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 118. Emcure Pharmaceuticals Limited Adult Malignant Glioma Treatment Product
    Table 119. Emcure Pharmaceuticals Limited Recent Developments/Updates
    Table 120. Bayer Corporation Information
    Table 121. Bayer Description and Business Overview
    Table 122. Bayer Adult Malignant Glioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 123. Bayer Adult Malignant Glioma Treatment Product
    Table 124. Bayer Recent Developments/Updates
    Table 125. SL Pharm Corporation Information
    Table 126. SL Pharm Description and Business Overview
    Table 127. SL Pharm Adult Malignant Glioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 128. SL Pharm Adult Malignant Glioma Treatment Product
    Table 129. SL Pharm Recent Developments/Updates
    Table 130. Boan Biotech Corporation Information
    Table 131. Boan Biotech Description and Business Overview
    Table 132. Boan Biotech Adult Malignant Glioma Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 133. Boan Biotech Adult Malignant Glioma Treatment Product
    Table 134. Boan Biotech Recent Developments/Updates
    Table 135. Key Raw Materials Lists
    Table 136. Raw Materials Key Suppliers Lists
    Table 137. Adult Malignant Glioma Treatment Distributors List
    Table 138. Adult Malignant Glioma Treatment Customers List
    Table 139. Adult Malignant Glioma Treatment Market Trends
    Table 140. Adult Malignant Glioma Treatment Market Drivers
    Table 141. Adult Malignant Glioma Treatment Market Challenges
    Table 142. Adult Malignant Glioma Treatment Market Restraints
    Table 143. Research Programs/Design for This Report
    Table 144. Key Data Information from Secondary Sources
    Table 145. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Adult Malignant Glioma Treatment
    Figure 2. Global Adult Malignant Glioma Treatment Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Adult Malignant Glioma Treatment Market Share by Type in 2023 & 2030
    Figure 4. Chemotherapy Product Picture
    Figure 5. Targeted Drug Therapy Product Picture
    Figure 6. Global Adult Malignant Glioma Treatment Market Value Comparison by Application (2024-2030) & (US$ Million)
    Figure 7. Global Adult Malignant Glioma Treatment Market Share by Application in 2023 & 2030
    Figure 8. Glioblastoma Multiforme
    Figure 9. Anaplastic Astrocytoma
    Figure 10. Anaplastic Oligodendroglioma
    Figure 11. Anaplastic Oligoastrocytoma
    Figure 12. Other
    Figure 13. Global Adult Malignant Glioma Treatment Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 14. Global Adult Malignant Glioma Treatment Market Size (2019-2030) & (US$ Million)
    Figure 15. Global Adult Malignant Glioma Treatment Sales (2019-2030) & (K Units)
    Figure 16. Global Adult Malignant Glioma Treatment Average Price (US$/Unit) & (2019-2030)
    Figure 17. Adult Malignant Glioma Treatment Report Years Considered
    Figure 18. Adult Malignant Glioma Treatment Sales Share by Manufacturers in 2023
    Figure 19. Global Adult Malignant Glioma Treatment Revenue Share by Manufacturers in 2023
    Figure 20. The Global 5 and 10 Largest Adult Malignant Glioma Treatment Players: Market Share by Revenue in 2023
    Figure 21. Adult Malignant Glioma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 22. Global Adult Malignant Glioma Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 23. North America Adult Malignant Glioma Treatment Sales Market Share by Country (2019-2030)
    Figure 24. North America Adult Malignant Glioma Treatment Revenue Market Share by Country (2019-2030)
    Figure 25. United States Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 26. Canada Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 27. Europe Adult Malignant Glioma Treatment Sales Market Share by Country (2019-2030)
    Figure 28. Europe Adult Malignant Glioma Treatment Revenue Market Share by Country (2019-2030)
    Figure 29. Germany Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 30. France Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 31. U.K. Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 32. Italy Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 33. Russia Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 34. Asia Pacific Adult Malignant Glioma Treatment Sales Market Share by Region (2019-2030)
    Figure 35. Asia Pacific Adult Malignant Glioma Treatment Revenue Market Share by Region (2019-2030)
    Figure 36. China Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 37. Japan Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 38. South Korea Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 39. India Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. Australia Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 41. China Taiwan Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 42. Southeast Asia Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 43. Latin America Adult Malignant Glioma Treatment Sales Market Share by Country (2019-2030)
    Figure 44. Latin America Adult Malignant Glioma Treatment Revenue Market Share by Country (2019-2030)
    Figure 45. Mexico Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 46. Brazil Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 47. Argentina Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 48. Middle East & Africa Adult Malignant Glioma Treatment Sales Market Share by Country (2019-2030)
    Figure 49. Middle East & Africa Adult Malignant Glioma Treatment Revenue Market Share by Country (2019-2030)
    Figure 50. Turkey Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 51. Saudi Arabia Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 52. UAE Adult Malignant Glioma Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 53. Global Sales Market Share of Adult Malignant Glioma Treatment by Type (2019-2030)
    Figure 54. Global Revenue Market Share of Adult Malignant Glioma Treatment by Type (2019-2030)
    Figure 55. Global Adult Malignant Glioma Treatment Price (US$/Unit) by Type (2019-2030)
    Figure 56. Global Sales Market Share of Adult Malignant Glioma Treatment by Application (2019-2030)
    Figure 57. Global Revenue Market Share of Adult Malignant Glioma Treatment by Application (2019-2030)
    Figure 58. Global Adult Malignant Glioma Treatment Price (US$/Unit) by Application (2019-2030)
    Figure 59. Adult Malignant Glioma Treatment Value Chain
    Figure 60. Adult Malignant Glioma Treatment Production Process
    Figure 61. Channels of Distribution (Direct Vs Distribution)
    Figure 62. Distributors Profiles
    Figure 63. Bottom-up and Top-down Approaches for This Report
    Figure 64. Data Triangulation
    Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Personalizing Cancer Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-26D6003
Sat Oct 12 00:00:00 UTC 2024

Add to Cart

Global Chemotherapy Chairs Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-26D13514
Sat Oct 12 00:00:00 UTC 2024

Add to Cart

Drugs for Non-Small Cell Lung Cancer - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-33S12067
Fri Oct 11 00:00:00 UTC 2024

Add to Cart

Oncological Phototherapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-11U13658
Tue Oct 08 00:00:00 UTC 2024

Add to Cart